TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11952268

Group type: EXPERIMENTAL
Intervention: Nonverbal conflict behaviors expressed in videotaped simulations of interadult disputes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expressions of fear
Number of subjects: 0
Study: 10890258

Group type: EXPERIMENTAL
Intervention: Fosfomycin (3-g single dose)
Number of subjects: 749

Group type: COMPARATOR
Intervention: Nitrofurantoin (100-mg capsules for 7 days)
Number of subjects: 749

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 749
Study: 7724749

Group type: EXPERIMENTAL
Intervention: L‐DOPA alone (n = 16)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: C‐11‐L‐DOPA and C‐11‐5‐HTP (n = 6)
Number of subjects: 22

Group type: COMPARATOR
Intervention: CT
Number of subjects: 22
Study: 2075773

Group type: EXPERIMENTAL
Intervention: Perioperative short-term antibiotic prophylaxis
Number of subjects: 162

Group type: COMPARATOR
Intervention: Postoperative antibiotic treatment
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 162
Study: 6942648

Group type: EXPERIMENTAL
Intervention: Soy diet
Number of subjects: 69

Group type: COMPARATOR
Intervention: Casein diet
Number of subjects: 69
Study: 30787601

Group type: EXPERIMENTAL
Intervention: 500 mg SBB‐PE
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29958855

Group type: EXPERIMENTAL
Intervention: Sofosbuvir and Velpatasvir for 12 weeks (n=101)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Sofosbuvir and Velpatasvir plus Ribavirin for 12 weeks (n=103)
Number of subjects: 204
Study: 26997182

Group type: EXPERIMENTAL
Intervention: Chewing tobacco use trajectory
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Multiple substance use trajectory
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Prescription drug misuse trajectory
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Alcohol use trajectory
Number of subjects: 684
Study: 25217039

Group type: EXPERIMENTAL
Intervention: SaltSwitch smartphone app
Number of subjects: 300

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 300
Study: 22381604

Group type: EXPERIMENTAL
Intervention: Immediate medical treatment (oral mifepristone followed by vaginal misoprostol, n = 91)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Sequential management (1 week of watchful waiting followed by medical treatment if necessary, n = 91)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Immediate medical treatment
Number of subjects: 182

Group type: COMPARATOR
Intervention: Sequential management
Number of subjects: 182
Study: 20628332

Group type: EXPERIMENTAL
Intervention: Home-based exercise (trunk muscle strengthening and stretching exercises)
Number of subjects: 201

Group type: COMPARATOR
Intervention: NSAIDs (control group)
Number of subjects: 201
Study: 17711944

Group type: EXPERIMENTAL
Intervention: TQS (Tétanos Quick Stick) test
Number of subjects: 611

Group type: COMPARATOR
Intervention: Standard vaccination history assessment without TQS
Number of subjects: 611
Study: 15607213

Group type: EXPERIMENTAL
Intervention: Timed 25-foot walk (T25FW)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Paced auditory serial addition test (PASAT)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 9-hole peg test (9HP)
Number of subjects: 32
Study: 12112798

Group type: EXPERIMENTAL
Intervention: salbutamol plus BDP 200 microg bid by metered dose inhaler (MDI) with a spacer
Number of subjects: 31

Group type: COMPARATOR
Intervention: salbutamol MDI plus a placebo
Number of subjects: 31
Study: 10354329

Group type: EXPERIMENTAL
Intervention: Teaching intervention on clinical reasoning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no teaching intervention)
Number of subjects: 0
Study: 7497688

Group type: EXPERIMENTAL
Intervention: Failed arthroplasty group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 1798317

Group type: EXPERIMENTAL
Intervention: Caffeine (10 mg.kg‐1) taken immediately prior to exercise
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control or placebo conditions
Number of subjects: 6
Study: 7019706

Group type: EXPERIMENTAL
Intervention: Early supervised exercise program
Number of subjects: 258

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 258
Study: 29120277

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 1107
Study: 26886503

Group type: EXPERIMENTAL
Intervention: DEVS program (intervention group)
Number of subjects: 1752

Group type: COMPARATOR
Intervention: Usual drug education program (control group)
Number of subjects: 1752
Study: 25046272

Group type: EXPERIMENTAL
Intervention: Subcutaneous MNX (0.9 mg/kg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 50
Study: 22777113

Group type: EXPERIMENTAL
Intervention: 7.5% hypertonic saline (HS)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 7.5% hypertonic saline + 6% dextran 70 (HSD)
Number of subjects: 34

Group type: COMPARATOR
Intervention: 0.9% normal saline (NS)
Number of subjects: 34
Study: 21063148

Group type: EXPERIMENTAL
Intervention: Two above one below approach with intermediate screws at the fracture site
Number of subjects: 27

Group type: COMPARATOR
Intervention: Long segment posterior spinal fusion
Number of subjects: 27
Study: 17927497

Group type: COMPARATOR
Intervention: Fish oil, 2 g tid plus placebo capsules bid (n = 12)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Fish oil, 2 g tid plus celecoxib 200 mg bid (n = 10)
Number of subjects: 34
Study: 15837438

Group type: EXPERIMENTAL
Intervention: Patient-specific electronically generated hypertension decision support system (DSS)
Number of subjects: 588

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 588
Study: 11856592

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with bone marrow or stem cell support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single agent chemotherapy (doxorubicin, epirubicin, ifosfamide)
Number of subjects: 0
Study: 9655795

Group type: EXPERIMENTAL
Intervention: Laser Doppler scanning during cold stress
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laser Doppler scanning during heat stress
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laser Doppler scanning during LBNP
Number of subjects: 0
Study: 8180354

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anticytokine treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiprotease treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Detection of cervical, decidual, and/or chorionic extracellular matrix proteins
Number of subjects: 0
Study: 2574304

Group type: EXPERIMENTAL
Intervention: AIK-C vaccine at 4-5 months
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb vaccine at 4-5 months
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: High-dose Schwarz vaccine at 4-5 months
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: High-dose Edmonston-Zagreb vaccine for seropositive children
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: AIK-C vaccine for seropositive children
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Schwarz vaccine for seropositive children
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: AIK-C vaccine at 8-10 months
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Schwarz vaccine at 8-10 months
Number of subjects: 5
Study: 29448880

Group type: EXPERIMENTAL
Intervention: Mobile-bearing single-radius TKP
Number of subjects: 46

Group type: COMPARATOR
Intervention: Fixed-bearing single-radius TKP
Number of subjects: 46
Study: 26939898

Group type: EXPERIMENTAL
Intervention: Xenon 30% (Xe/O2 30%/60%)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control gas (N2/O2 40%/60%)
Number of subjects: 24
Study: 24589938

Group type: COMPARATOR
Intervention: Video computer tailoring (n=670)
Number of subjects: 2099

Group type: COMPARATOR
Intervention: Text computer tailoring (n=708)
Number of subjects: 2099

Group type: EXPERIMENTAL
Intervention: Control condition (n=721)
Number of subjects: 2099
Study: 22364371

Group type: EXPERIMENTAL
Intervention: Fully and protagonist‐perspective labeled conditions
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Labeling the nondominant belief
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Labeling manipulations
Number of subjects: 165
Study: 19833566

Group type: EXPERIMENTAL
Intervention: Leukocytapheresis (LAP) plus steroids
Number of subjects: 18
Study: 19032173

Group type: EXPERIMENTAL
Intervention: 1.5 g piperacillin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 3 g piperacillin
Number of subjects: 10
Study: 15927814

Group type: EXPERIMENTAL
Intervention: FX cream (0.02% farnesol and 5% xylitol)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 17
Study: 12831141

Group type: EXPERIMENTAL
Intervention: Latanoprost (topically applied once daily in the evening for 12 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Brimonidine (applied twice daily for 6 weeks, with 16 patients continuing for 12 weeks)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 28

Group type: COMPARATOR
Intervention: Brimonidine
Number of subjects: 28
Study: 11322147

Group type: EXPERIMENTAL
Intervention: Lumbar corset
Number of subjects: 12

Group type: COMPARATOR
Intervention: No lumbar corset
Number of subjects: 12
Study: 8796775

Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl (50 micrograms)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no fentanyl)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups (fentanyl and control)
Number of subjects: 24
Study: 8382104

Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/day for an average of 8 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20
Study: 3654235

Group type: EXPERIMENTAL
Intervention: ACT‐Asma Control y Tratamiento Para Niños (asthma educational program)
Number of subjects: 0
Study: 29582517

Group type: EXPERIMENTAL
Intervention: Early motivational interviewing (3 individual sessions by nurses or social workers prior to hospital discharge)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 48
Study: 28712152

Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide (HP) with LED blue/laser infrared activation
Number of subjects: 31

Group type: COMPARATOR
Intervention: 35% hydrogen peroxide (HP) control
Number of subjects: 31
Study: 27045127

Group type: EXPERIMENTAL
Intervention: Comprehensive Cardiac Rehabilitation combined with Stress Management Training (CR+SMT)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Comprehensive Cardiac Rehabilitation (CR) alone
Number of subjects: 151

Group type: COMPARATOR
Intervention: Comprehensive Cardiac Rehabilitation (CR) groups (both CR and CR+SMT)
Number of subjects: 151
Study: 23816022

Group type: EXPERIMENTAL
Intervention: Canada Acute Coronary Syndrome Risk Score (C-ACS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C-ACS score of 0
Number of subjects: 0
Study: 22156181

Group type: EXPERIMENTAL
Intervention: Additional written information about orthodontic treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Additional written information about fluoride
Number of subjects: 80
Study: 20112575

Group type: EXPERIMENTAL
Intervention: Cheezheng Qingpeng ointment
Number of subjects: 78

Group type: COMPARATOR
Intervention: Diclofenac diethylamine emugel
Number of subjects: 78
Study: 16936533

Group type: EXPERIMENTAL
Intervention: Low-dose fixed combination of perindopril 2 mg and indapamide 0.625 mg
Number of subjects: 12140

Group type: EXPERIMENTAL
Intervention: Intensive gliclazide-MR-based glucose control regimen targeting HbA1c of 6.5% or less
Number of subjects: 12140

Group type: COMPARATOR
Intervention: Standard guidelines based therapy for glucose control
Number of subjects: 12140
Study: 15495877

Group type: EXPERIMENTAL
Intervention: Rural cancer patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Urban cancer patients
Number of subjects: 0
Study: 11783459

Group type: EXPERIMENTAL
Intervention: Herbal anticellulite pill plus supplements of conjugated linoleic acid
Number of subjects: 60

Group type: COMPARATOR
Intervention: Herbal anticellulite pill
Number of subjects: 60
Study: 9051503

Group type: EXPERIMENTAL
Intervention: Silicone intraocular lens (IOL) implantation through a 3.2 mm incision
Number of subjects: 120

Group type: COMPARATOR
Intervention: Poly(methyl methacrylate) IOL implantation through a 4.0 mm incision
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups (3.2 mm and 4.0 mm incisions)
Number of subjects: 120
Study: 1651610

Group type: EXPERIMENTAL
Intervention: Serotype 1 reassortant vaccine (10^4 p.f.u.)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Serotype 2 reassortant vaccine (10^4 p.f.u.)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination of serotype 1 and serotype 2 vaccines (0.5 x 10^4 p.f.u. of each)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Trivalent combination (0.33 x 10^4 p.f.u. of each strain)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Various vaccines and combinations
Number of subjects: 100
Study: 6321376

Group type: EXPERIMENTAL
Intervention: 40 mg ORG 2766
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 30883053

Group type: EXPERIMENTAL
Intervention: TAVR with a self-expanding supraannular bioprosthesis
Number of subjects: 1403

Group type: COMPARATOR
Intervention: Surgical aortic-valve replacement
Number of subjects: 1403

Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 1403

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 1403
Study: 27659218

Group type: EXPERIMENTAL
Intervention: Bilastine 20 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Rupatadine 10 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 25132516

Group type: COMPARATOR
Intervention: PEGASUS psychoeducational programme (n = 24), administered in six weekly group sessions.
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group receiving no additional intervention (n = 24).
Number of subjects: 48
Study: 24001010

Group type: EXPERIMENTAL
Intervention: Spontaneous inhibitor clearance in patients not undergoing ITI
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Inhibitor titre and gene mutation
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Cumulative incidence of inhibitors
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Permanent inhibitors
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Transient inhibitors
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Additional category of patients
Number of subjects: 524
Study: 21860049

Group type: EXPERIMENTAL
Intervention: Training of Affect Recognition (TAR)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Cognitive Remediation Training (CRT)
Number of subjects: 38
Study: 19922681

Group type: EXPERIMENTAL
Intervention: Combination reverse transcriptase inhibitors
Number of subjects: 0
Study: 17257428

Group type: EXPERIMENTAL
Intervention: Urodilatin (URO) infusion for 90 minutes
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 15508665

Group type: EXPERIMENTAL
Intervention: Breathing through a face mask with an ITD (impedance of 6 cm H2O)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Breathing through a face mask with a sham ITD (control)
Number of subjects: 20
Study: 11869325

Group type: EXPERIMENTAL
Intervention: Botulinum toxin (BT) injection (80 units in five cases, 60 units in two cases) into four quadrants of lower esophageal sphincter (LES)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Pneumatic dilatation by Rigiflex dilator
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Both therapies (BT and pneumatic dilatation)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Cumulative dysphagia-free state
Number of subjects: 17
Study: 9272237

Group type: EXPERIMENTAL
Intervention: Levosimendan 1 mg intravenously
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Levosimendan combined with ethanol orally
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ethanol 0.8 g/kg alone
Number of subjects: 12
Study: 8591371

Group type: EXPERIMENTAL
Intervention: Knowledge-based medical record (intervention group); 191 patients
Number of subjects: 349

Group type: COMPARATOR
Intervention: Control group; 158 patients
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Knowledge-based medical record (intervention group)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 349
Study: 2688125

Group type: EXPERIMENTAL
Intervention: Danzen (Serrapeptase)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 1169822

Group type: EXPERIMENTAL
Intervention: Intravenous dextran 40
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin
Number of subjects: 271

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 271
Study: 31546613

Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation and Therapeutic Exercises (FES+TE)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Therapeutic Exercises (TE)
Number of subjects: 5
Study: 28409563

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Minimal-contact waitlist
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Combined OCD participants (CBT-only plus waitlist-CBT)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Pre-CBT Glu levels in vPCC
Number of subjects: 49
Study: 25982235

Group type: EXPERIMENTAL
Intervention: Flexion group (knee flexed at 45°)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Extension group (knee fully extended)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Flexion group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 24052987

Group type: EXPERIMENTAL
Intervention: Vitamin E (400 mg/day for at least 6 months)
Number of subjects: 14
Study: 25665208

Group type: EXPERIMENTAL
Intervention: Combined dose of 5 mg x kg(‐1) of body weight of caffeine and 200 mg of Panax ginseng
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 19909587

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor (letrozole, 5 mg/day) + rFSH (450 IU/day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: rFSH (450 IU/day) alone
Number of subjects: 70
Study: 16802289

Group type: EXPERIMENTAL
Intervention: EMF-on (real exposure)
Number of subjects: 15

Group type: COMPARATOR
Intervention: EMF-off (sham exposure)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Tympanic temperature
Number of subjects: 15
Study: 15564955

Group type: COMPARATOR
Intervention: Haloperidol 0.5-4 mg
Number of subjects: 2468

Group type: COMPARATOR
Intervention: Haloperidol 1 mg
Number of subjects: 2468

Group type: COMPARATOR
Intervention: Haloperidol 2 mg
Number of subjects: 2468

Group type: COMPARATOR
Intervention: Haloperidol 4 mg
Number of subjects: 2468

Group type: COMPARATOR
Intervention: Haloperidol 5 mg
Number of subjects: 2468
Study: 10673291

Group type: EXPERIMENTAL
Intervention: Quadruple antibiotic therapy for one day
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Quadruple antibiotic therapy for two days
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Patients with cagA+/vacA s1 H pylori strains
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Patients with peptic ulcer disease
Number of subjects: 121
Study: 9300248

Group type: EXPERIMENTAL
Intervention: High fasting plasma NEFA in NGT subjects
Number of subjects: 4089

Group type: EXPERIMENTAL
Intervention: High 2-h plasma NEFA and low 2-h plasma insulin concentrations in IGT subjects
Number of subjects: 4089

Group type: EXPERIMENTAL
Intervention: Plasma NEFA concentration at baseline
Number of subjects: 4089

Group type: EXPERIMENTAL
Intervention: 2-h plasma insulin concentration in subjects with IGT who deteriorated
Number of subjects: 4089
Study: 8449086

Group type: EXPERIMENTAL
Intervention: 1.4 percent sodium citrate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Heparin 4 U/ml
Number of subjects: 40
Study: 3518910

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate 200 mg intramuscularly weekly for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: No additional therapy (Control)
Number of subjects: 0
Study: 30167699

Group type: EXPERIMENTAL
Intervention: Laryngeal Tube (LT)
Number of subjects: 3004

Group type: COMPARATOR
Intervention: Endotracheal Intubation (ETI)
Number of subjects: 3004
Study: 27283930

Group type: EXPERIMENTAL
Intervention: OSEM reconstruction for pre- and posttherapeutic PET (OSEMPET1/OSEMPET2)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: PSF ± TOF reconstruction for pre- and OSEM reconstruction for posttherapeutic PET (PSF ± TOFPET1/OSEMPET2)
Number of subjects: 86

Group type: COMPARATOR
Intervention: PSF ± TOF reconstruction for pre- and posttherapeutic PET (PSF ± TOFPET1/OSEMPET2)
Number of subjects: 86

Group type: COMPARATOR
Intervention: OSEM reconstruction for pre- and PSF ± TOF reconstruction for posttherapeutic PET (OSEMPET1/PSF ± TOFPET2)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Proprietary software tool applied to PSF ± TOF data
Number of subjects: 86
Study: 24635110

Group type: EXPERIMENTAL
Intervention: Training with TheraBite(®) Jaw Motion Rehabilitation System(™)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Patients receiving 3D conformal radiotherapy
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Patients treated with RT and concurrent chemotherapy
Number of subjects: 66
Study: 22221565

Group type: EXPERIMENTAL
Intervention: Low SES
Number of subjects: 4423

Group type: COMPARATOR
Intervention: High SES
Number of subjects: 4423

Group type: EXPERIMENTAL
Intervention: Black patients
Number of subjects: 4423

Group type: EXPERIMENTAL
Intervention: White patients
Number of subjects: 4423
Study: 20546509

Group type: EXPERIMENTAL
Intervention: Duloxetine 60/120 mg/day
Number of subjects: 181

Group type: COMPARATOR
Intervention: Duloxetine 60 mg/day (for previously placebo-treated patients)
Number of subjects: 181